Cargando…
Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma
The study aims to explore the diagnostic value of anti-GNA11 autoantibody in esophageal squamous cell carcinoma (ESCC) from multiple levels. Autoantibody against GNA11 with the highest diagnostic performance was screened out from the customized protein microarray. A total of 486 subjects including E...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462091/ https://www.ncbi.nlm.nih.gov/pubmed/34568004 http://dx.doi.org/10.3389/fonc.2021.661043 |
_version_ | 1784572126817157120 |
---|---|
author | Wang, Huimin Yang, Xiaoang Sun, Guiying Yang, Qian Cui, Chi Wang, Xiao Ye, Hua Dai, Liping Shi, Jianxiang Zhang, Jianying Wang, Peng |
author_facet | Wang, Huimin Yang, Xiaoang Sun, Guiying Yang, Qian Cui, Chi Wang, Xiao Ye, Hua Dai, Liping Shi, Jianxiang Zhang, Jianying Wang, Peng |
author_sort | Wang, Huimin |
collection | PubMed |
description | The study aims to explore the diagnostic value of anti-GNA11 autoantibody in esophageal squamous cell carcinoma (ESCC) from multiple levels. Autoantibody against GNA11 with the highest diagnostic performance was screened out from the customized protein microarray. A total of 486 subjects including ESCC patients and matched normal controls were recruited in the verification and validation phases by using enzyme-linked immunosorbent assay (ELISA). Western blotting analysis was used to verify the ELISA results. Immunohistochemistry (IHC) was used to evaluate GNA11 expression in ESCC tissues and para-tumor tissues. In addition, a bioinformatics approach was adopted to investigate the mRNA expression of GNA11 in ESCC. Results indicated that the level of anti-GNA11 autoantibody in ESCC patients was significantly higher than that in the normal controls, and it can be used to distinguish ESCC patients from normal individuals in clinical subgroups (p < 0.05), as revealed by both ELISA and Western blotting. The receiver operating characteristic (ROC) curve analysis showed that anti-GNA11 autoantibody could distinguish ESCC patients from normal controls with an area under the ROC curve (AUC) of 0.653, sensitivity of 10.96%, and specificity of 98.63% in the verification cohort and with an AUC of 0.751, sensitivity of 38.24%, and specificity of 88.82% in the validation cohort. IHC manifested that the expression of GNA11 can differentiate ESCC tissues with para-tumor tissues (p < 0.05), but it cannot be used to differentiate different pathological grades and clinical stages (p > 0.05). The mRNA expression of GNA11 in ESCC patients and normal controls was different with a bioinformatics mining with The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data in Gene Expression Profiling Interactive Analysis (GEPIA). In summary, anti-GNA11 autoantibody has the potential to be a new serological marker in the diagnosis of ESCC. |
format | Online Article Text |
id | pubmed-8462091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84620912021-09-25 Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma Wang, Huimin Yang, Xiaoang Sun, Guiying Yang, Qian Cui, Chi Wang, Xiao Ye, Hua Dai, Liping Shi, Jianxiang Zhang, Jianying Wang, Peng Front Oncol Oncology The study aims to explore the diagnostic value of anti-GNA11 autoantibody in esophageal squamous cell carcinoma (ESCC) from multiple levels. Autoantibody against GNA11 with the highest diagnostic performance was screened out from the customized protein microarray. A total of 486 subjects including ESCC patients and matched normal controls were recruited in the verification and validation phases by using enzyme-linked immunosorbent assay (ELISA). Western blotting analysis was used to verify the ELISA results. Immunohistochemistry (IHC) was used to evaluate GNA11 expression in ESCC tissues and para-tumor tissues. In addition, a bioinformatics approach was adopted to investigate the mRNA expression of GNA11 in ESCC. Results indicated that the level of anti-GNA11 autoantibody in ESCC patients was significantly higher than that in the normal controls, and it can be used to distinguish ESCC patients from normal individuals in clinical subgroups (p < 0.05), as revealed by both ELISA and Western blotting. The receiver operating characteristic (ROC) curve analysis showed that anti-GNA11 autoantibody could distinguish ESCC patients from normal controls with an area under the ROC curve (AUC) of 0.653, sensitivity of 10.96%, and specificity of 98.63% in the verification cohort and with an AUC of 0.751, sensitivity of 38.24%, and specificity of 88.82% in the validation cohort. IHC manifested that the expression of GNA11 can differentiate ESCC tissues with para-tumor tissues (p < 0.05), but it cannot be used to differentiate different pathological grades and clinical stages (p > 0.05). The mRNA expression of GNA11 in ESCC patients and normal controls was different with a bioinformatics mining with The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data in Gene Expression Profiling Interactive Analysis (GEPIA). In summary, anti-GNA11 autoantibody has the potential to be a new serological marker in the diagnosis of ESCC. Frontiers Media S.A. 2021-09-10 /pmc/articles/PMC8462091/ /pubmed/34568004 http://dx.doi.org/10.3389/fonc.2021.661043 Text en Copyright © 2021 Wang, Yang, Sun, Yang, Cui, Wang, Ye, Dai, Shi, Zhang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Huimin Yang, Xiaoang Sun, Guiying Yang, Qian Cui, Chi Wang, Xiao Ye, Hua Dai, Liping Shi, Jianxiang Zhang, Jianying Wang, Peng Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma |
title | Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma |
title_full | Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma |
title_fullStr | Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma |
title_full_unstemmed | Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma |
title_short | Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma |
title_sort | identification and evaluation of autoantibody to a novel tumor-associated antigen gna11 as a biomarker in esophageal squamous cell carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462091/ https://www.ncbi.nlm.nih.gov/pubmed/34568004 http://dx.doi.org/10.3389/fonc.2021.661043 |
work_keys_str_mv | AT wanghuimin identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT yangxiaoang identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT sunguiying identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT yangqian identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT cuichi identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT wangxiao identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT yehua identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT dailiping identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT shijianxiang identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT zhangjianying identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma AT wangpeng identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma |